Exelixis (EXEL) fundamentals: P/E, valuation, undervalued?
Exelixis · Health Care · ref. ETF XLV · price $59.51
In short — Exelixis trades at 18.9× earnings (P/E), 13.9× forward, with a net margin of 35.3 % and revenue growth of +11 %. Read: Cheap for the growth (P/E 14 for ~26% growth (PEG 0.5)).
Is Exelixis stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$59.51+50.6% over range
Oct 14, 25low $34.54 · high $59.86Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
27% recommend buying · 11 analysts
Valuation : Cheap for the growth — P/E 14 for ~26% growth (PEG 0.5)
Valuation
18.9
P/E (price/earnings)
13.9
Forward P/E
0.72
PEG
8.0
Price/book (P/B)
$14.7B
Market cap
3.15
EPS
Profitability & growth
35.3 %
Net margin
+11 %
Revenue growth
+26 %
Earnings growth
$166M
Total debt
Exelixis income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $1.6B | $182M | 11.3 % |
| 2023 | $1.8B | $208M | 11.4 % |
| 2024 | $2.2B | $521M | 24.0 % |
| 2025 | $2.3B | $783M | 33.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Exelixis's P/E and is the stock undervalued? What's a good P/E?
Exelixis's P/E is 18.9 (forward 13.9). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Cheap for the growth".
Is Exelixis profitable?
Exelixis has a net margin of 35.3 % (EPS 3.15). The company is profitable.
Is EXEL stock expensive?
Our read: "Cheap for the growth" — P/E 14 for ~26% growth (PEG 0.5). Cross-check with growth and sector.
💬 A question about Exelixis? The JPI assistant answers using our backtest data.
Keep exploring Exelixis